Xencor (NASDAQ:XNCR) Reaches New 1-Year Low – Time to Sell?

Shares of Xencor, Inc. (NASDAQ:XNCR) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $12.23 and last traded at $12.61, with a volume of 61223 shares. The stock had previously closed at $12.95.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on XNCR. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Price Performance

The stock has a market capitalization of $868.09 million, a P/E ratio of -3.85 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company’s 50-day simple moving average is $16.22 and its 200-day simple moving average is $20.30.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in XNCR. Wellington Management Group LLP acquired a new stake in Xencor during the 4th quarter valued at $632,000. California State Teachers Retirement System raised its position in shares of Xencor by 12.1% in the fourth quarter. California State Teachers Retirement System now owns 59,130 shares of the biopharmaceutical company’s stock valued at $1,359,000 after purchasing an additional 6,376 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of Xencor during the 4th quarter worth about $101,000. GF Fund Management CO. LTD. bought a new stake in shares of Xencor during the 4th quarter worth about $34,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Xencor in the 4th quarter valued at about $1,227,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.